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a  b  s  t  r  a  c  t
Objective: The ratio of monocytes to lymphocytes in peripheral blood could reﬂect an indi-
vidual’s immunity to Mycobacterium tuberculosis.  The objective of this study was to evaluate
the  relationship between ratio of monocytes to lymphocytes and clinical status of patients
with active tuberculosis.
Methods: This was a retrospective review of data collected from the clinical database of
The  Fifth People’s Hospital of Wuxi, Medical College of Jiangnan University. A total of 419
patients who had newly diagnosed active tuberculosis and 108 cases from 419 patients with
tuberculosis therapy either near completion or completed were selected. Controls were 327
healthy donors.
Results: Median ratio of monocytes to lymphocytes was 0.36 (IQR, 0.22–0.54) in patients
before treatment, and 0.16 (IQR, 0.12–0.20) in controls (p < 0.001). Ratio of monocytes to
lymphocytes <9% or >25% was signiﬁcant predictors for active tuberculosis (OR = 114.73,
95%  CI, 39.80–330.71; OR = 89.81, 95% CI, 53.18–151.68, respectively). After treatment, the
median ratio of monocytes to lymphocytes recovered to be nearly normal. Compared to
other patients, patients with extrapulmonary tuberculosis and of age >60 years were more
likely  to have extreme ratio of monocytes to lymphocytes (AOR = 2.57, 95% CI, 1.08–6.09;
AOR  = 4.36, 95% CI, 1.43–13.29, respectively).Conclusions: Ratio of monocytes to lymphocytes <9% or >25% is predictive of active tubercu-
losis.∗ Corresponding author.
E-mail address: j.wang1988@hotmail.com (J. Wang).
1 These authors contributed equally to this article.
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Introduction
Globally there were an estimated 8.6 million new cases of
tuberculosis (TB) in 2013 and 1.3 million deaths.1 China and
India have the greatest burden of disease. India and China
alone accounted for 26% and 12% of total cases, respectively.1
In the most Western European countries and United States,
the majority of cases occur in foreign-born residents and
recent immigrants from countries in which TB is endemic.2–4
TB is presenting new challenges as a global health prob-
lem, especially with new threats of HIV coinfection and
drug-resistant strains of Mycobacterium tuberculosis (Mtb).5 The
knowledge about the hematological manifestations of Mtb
infection is critically important to provide insight into patho-
genesis. For decades, myeloid-speciﬁc cells have been known
to serve as host cells for Mtb  growth and lymphoid cells are
thought to be the major effector cells in TB immunity. Given
the central role of monocytes and lymphocytes in the induc-
tion of immune responses, their levels (hereafter termed “ML
ratio”) in peripheral blood might be expected to reﬂect the
state of an individual’s immunity to infection.
In a recent clinical analysis of peripheral blood mono-
nuclear cells from a cohort of South African infants the relative
ratio of monocytes to lymphocytes at the start of monitoring
was shown to predict risk of developing tuberculosis disease
during follow-up.6
Others reported that the ratio of lymphocytes to monocytes
in peripheral blood correlated with the extent of tuberculo-
sis in both rabbits7 and humans,8 but the numbers studied
were small and the strength of the conclusions that could be
reached in humans was deemed to be modest. The direct char-
acterization of ML  ratio to date has been surprisingly limited.
There was no strong evidence that ML  ratio was affected by
Mtb  infection in humans.
To start with this, using full differential blood count data
from patients with active tuberculosis and healthy donors, we
sought to determine whether ML  ratio could be affected by
tuberculosis or ongoing anti-TB treatment and provide insight
into its pathogenesis.
Method
Study  population  and  ethics  statement
Data from all subjects in the present retrospective review
were collected from the clinical database of The Fifth People’s
Hospital of Wuxi, Afﬁliated to Jiangnan University, between
December 2010 and June 2013. This study was approved by the
Institutional Ethics Committee of The Fifth People’s Hospital
of Wuxi, Afﬁliated to Jiangnan University (QD-2013-0016), and
was in compliance with the national legislation and the Dec-
laration of Helsinki guidelines. Written patient consent was
obtained according to the institutional guidelines.Participants  clinical  diagnosis  and  treatment
Healthy donors were from the physical examination center
of our hospital and met  the following criteria: no history ofFig. 1 – Patient selection criteria used in this study.
previous active TB or TB treatment, no evidence of current
active TB (absence of cough, intermittent fever, and exces-
sive night sweating in the past two weeks and absence of
unexplained weight loss in the past month). Tuberculosis was
diagnosed when subjects with clinical and/or imaging features
compatible with tuberculosis had at least one of the follow-
ing criteria: positive sputum smear for acid-fast bacilli (AFB);
positive culture for M. tuberculosis; biopsy suggestive of tuber-
culosis, and/or full response to anti-tuberculosis treatment.
Patients with extrapulmonary TB accompanying pulmonary
TB involvement were included in the category of extrapul-
monary TB. Treatment of new cases, both pulmonary and
extrapulmonary tuberculosis, received two months of isoni-
azid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)
during an intensive phase and four months of HR in the con-
tinuation phase. The duration of treatment was six months.
Several kinds of extrapulmonary tuberculosis were more  dif-
ﬁcult to cure. Treatment for an extended period of time was
required to ensure disease control. Such as, prolonged therapy
had been adopted in TB meningitis (9–12 months) and bone
and joint TB (9 months; Fig. 1).9
Full  differential  blood  countsFull blood counts (FBC) of peripheral blood collected in
ethylene-diamine tetra-acetic acid containing (EDTA) tubes
were performed by one of two clinical diagnostic laborato-
ries each using a ﬁve-part differential hematology analyser
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Table 1 – Demographic, clinical, and laboratory characteristics of the study population.
Characteristic Value
Active tuberculosis (n = 419) Healthy donors (n = 327) p-valuea
Age (year) 55  (33–69) 54 (38–67) 0.96
No. (%) of male subjectsb 298 (71.1) 207 (63.3) 0.02
Cell count (per dm3)c
WBC 7.10 (5.51–9.20) 6.32 (5.35–7.35) <0.001
Monocytes 0.50 (0.30–0.67) 0.35 (0.29–0.43) <0.001
Lymphocytes 1.39 (1.02–1.80) 2.23 (1.83–2.71) <0.001
ML ratio 0.36 (0.22–0.54) 0.16 (0.12–0.20) <0.001
Neutrophils 4920 (3480–6990) 3510 (2780–4280) <0.001





































ab Data are presented as numbers (%) of individuals except indicated.
c Data are presented as median numbers (interquartile range).
Sysmex Model XS, Hamburg, Germany). Full blood count mea-
urement was subject to strict quality assurance procedures
ncluding twice-daily high and low internal quality control,
ortnightly quality controls done by the Wuxi clinical labo-
atory QC scheme (Wuxi, Jiangsu, China) and annual quality
ssurance as part of Jiangsu clinical laboratory QC scheme.
oth laboratories are accredited by the China National Accred-
tation System in accordance with international standards ISO
7025/2005 and ISO 15189/2007.
tatistical  methods
tatistical analysis was conducted using SPSS version 17.0.
earson’s chi-square test and Mann–Whitney U test were used
o identify signiﬁcant differences across patients and healthy
onors, patients before treatment and after treatment. p < 0.05
two-sided) was considered as statistically signiﬁcant differ-
nce. The odds ratios (OR) were estimated with 95% conﬁdence
ntervals (CIs) from the univariate analysis to investigate the
elationship between active tuberculosis and the different ML
atios. Adjusted odds ratios (AOR) with 95% CIs were also esti-
ated from the multivariate analysis to determine the factors
ssociated with the different ML  ratios of patients.
esults
haracteristics  of  the  study  population
 total of 1068 patients were diagnosed with active TB in
he database of The Fifth People’s Hospital of Wuxi from
ecember 2010 to June 2013. Availability of full differential
lood counts when newly diagnosed with active TB (previ-
usly untreated for TB and never received anti-TB drugs for <1
onth) was required to compare with healthy donors. Patients
ithout pre-treatment data were excluded and 965 patients
emained. We  further excluded return-visiting patients, who
xperienced treatment failure or reinfection during the course
f therapy, 638 patients remained. After excluding patients
ith viral hepatitis (viral hepatitis type A, B and C), AIDS
acquired immune deﬁciency syndrome), and diabetes, 464
atients remained. Individuals who were pregnant, did not
gree to participate in our study, or had other diseases, suchas, lung cancer, measles, syphilis, leucopenia, systemic lupus
erythematosus, or rheumatoid arthritis, which were likely to
inﬂuence full blood counts, were also excluded. Finally, data
of full blood counts from 419 patients were included in the
analysis, with a median age of 55 years, and 71.1% were
men. Furthermore, in order to assess the inﬂuence of anti-TB
therapy, we  excluded patients who did not receive the rec-
ommended therapy, such as irregular treatment, intermittent
treatment, and undertreated patients. Finally, 108 patients
who had anti-TB therapy either near completion or completed
remained. A total of 327 healthy volunteers were included, 207
male and 120 female subjects.
Demographic,  clinical,  and  laboratory  characteristics  of
the study  sample
There were 746 individuals enrolled in the study: 419 patients
with newly treated active tuberculosis, and 327 healthy donors
without Mtb infection. Demographic and clinical character-
istics and laboratory data are summarized in Table 1. There
was no difference in median age or sex between patients and
healthy donors. Patients with active tuberculosis had signif-
icantly higher median absolute number of white blood cell
(WBC), monocytes and neutrophils than healthy donors. The
median absolute number of lymphocytes of patients was sig-
niﬁcantly lower than that of healthy donors. Patients with
active tuberculosis had a signiﬁcantly different ML ratio to
healthy donors.
Association  between  ML  ratio  and  active  tuberculosis,  by
percentile  ranking  of  the  ratio  of  monocytes  to  lymphocytes
Participants (patients and healthy donors) were stratiﬁed into
categories of ML ratio of less than the 9th percentile, between
the 9th and 25th percentile, and greater than the 25th per-
centile (Table 2). Compared to healthy donors, patients with
active tuberculosis were distributed differently in the three
categories: 73.9% of patients compared to 24% of healthy
donors with ML  ratio >the 25th percentile, 15.8% to 1.2% with
ML ratio <the 9th percentile, and 10.3% to 91.4% with ML  ratio
between the 9th and 25th percentile, the difference was statis-
tically signiﬁcant by multi-classiﬁcation analysis of Pearson’s
chi-square test (p < 0.001) (Table 2). As shown in Fig. 2, ML  ratio
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p-valuea ORa 95.0% CI for OR
Lower  Upper
ML ratio between 9th and 25th percentile 43 (10.3) 299 (91.4) 1
ML ratio <9th percentile 66 (15.8) 4 (1.2) <0.001 114.733 39.803 330.716
ML ratio >25th percentile 310 (73.9) 24 (7.4) <0.001 89.816 53.181 151.687
p-valueb <0.001
a Logistic regression analysis, abbreviations: OR, odds ratio; CI, conﬁdence interval.
b Pearson’s chi-square test.
of healthy donors (blue circle) centralized mostly between the
blue and green lines (91.4%); ML  ratio of patients (green cir-
cle) distributed mainly out of the lines (89.7%) (Fig. 2A). ML
ratio of healthy donors was the most centralized data (IQR
0.08), and gathered mainly in the area where the data from
patients distributed rarely (Fig. 2B). Compared to ML  ratio
between the 9th and 25th percentile, participants with ML
ratio <the 9th percentile or >the 25th percentile had a higher
likelihood to be patients with active tuberculosis (OR = 114.73,
95% CI, 39.80–330.71; OR = 89.81, 95% CI, 53.18–151.68, respec-
tively) (Table 2). It indicated that ML  ratio less than the 9th
percentile or greater than the 25th percentile were signiﬁcant
predictors for active tuberculosis.
Factors  associated  with  different  ML  ratio  distribution  in
334 patientsA multivariate analysis was conducted using variables of gen-
der, age and disease classiﬁcation. As shown in Table 3, our
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Fig. 2 – Distribution of participants (patients and healthy donors
Monocytes and lymphocytes count are plotted on the x- and y-ax
centralized mostly between the blue and green lines, ML  ratio of
The dotted blue line denotes the 9th percentiles for ML  ratio. The
ratios. (B) Median levels of ML  ratio of patients of active tuberculo
individual patient or healthy donor. Bars represent medians. ML
the data from patients distributed rarely.who had clear information of disease classiﬁcation. Male
patients had a higher probability to be in the group of ML  ratio
<9% or ML ratio >25% than female patients, but the result had
no statistical signiﬁcance. Compared to patients less than 23
years of age, patients older than 60 years were over 4-fold
more likely to be in the group of ML ratio <9% or ML  ratio
>25%. Patients with extrapulmonary tuberculosis were nearly
2.5-fold more  likely to be in the extreme groups (Table 3).
ML  ratio  of  patients  recovered  to  be  nearly  normal  with
treatment
In order to further evaluate the impact of anti-TB therapy on
the ML  ratio, we  excluded patients who did not receive the
recommended therapy, such as irregular treatment, intermit-
tent treatment, and undertreated therapy. A total of 108 from
419 patients who had FBC with therapy either near comple-
tion or completed were remaining and was also stratiﬁed into
the same three categories with ML ratio: less than the 9th per-


















) with ratio of monocytes to lymphocytes (ML ratio). (A)
es, respectively. ML  ratio of healthy donors (blue circle)
 patients (green circle) distributed mainly out of the lines.
 dotted green line denotes the 25th percentiles for ML
sis and healthy donors. Each dot represents ML  ratio for an
 ratio of healthy donors gathered mainly in the area where
b r a z j i n f e c t d i s . 2 0 1 5;1 9(2):125–131 129
Table 3 – Factors associated with different ML  ratios distribution of patients diagnosed with active tuberculosis.
Active tuberculosis Value
ML ratio <9th percentile
or ML ratio >25th
percentile (304)
ML ratio between 9th
and 25th percentile (30)
p-valuea AORa 95.0% CI for AOR
Lower Upper
Gender
Male 216 (71) 24 (80) 1
Female 88 (29) 6 (20) 0.263 1.729 0.663 4.508
Age
<23 42 (13.8) 8 (26.7) 1
23–60 130 (42.8) 12 (40) 0.076 2.537 0.907 7.097
>60 132 (43.4) 10 (33.3) 0.01 4.364 1.433 13.296
Classiﬁcationb
Pulmonary tuberculosis 180 (59.2) 21 (79) 1
Extrapulmonary tuberculosis 124 (40.8) 9 (30) 0.032 2.571 1.085 6.093




































t85 cases lack clear information of disease classiﬁcation.
he 25th percentile. Anti-TB therapy signiﬁcantly reduced ML
atio with ML  ratio greater than 25th percentile (median ML
atio, 0.472 (IQR, 0.33–0.62) before treatment vs 0.2199 (IQR,
.16–0.28) after treatment, p < 0.001). ML  ratio elevated signif-
cantly with ML  ratio less than 9th percentile (median ML
atio, 0.026 (IQR, 0.006–0.059) before treatment vs 0.197 (IQR,
.09–0.25) after treatment, p < 0.001). In patients with ML ratio
etween the 9th and 25th percentile, there was no differ-
nce between ML  ratio before treatment (median ML ratio,
.20 [IQR 0.15–0.23]) and after treatment (median ML ratio,
.15 [IQR, 0.12–0.19], p = 0.166). Before anti-TB therapy, 9.3% of
ndividuals (10/108) had ML  ratio between the 9th and 25th
ercentile, compared with 75% (81/108) following anti-TB ther-
py (p < 0.001). The median ML  ratio of healthy donors was
.15 (IQR, 0.12–0.19). The results indicated that higher ML  ratio
ecreased, and lower ML  ratio increased to be close to the ML
atio of healthy donors. ML  ratio of patients recovered to be
early normal with treatment.
iscussion
onocytes are an essential component of the innate immune
esponse that acts as a link to the adaptive immune system
hrough antigen presentation to lymphocytes. Thus any fac-
or that perturbs the function or relative numbers of either
ell type could potentially affect an individual’s response to
nfection.
The ML  ratio in peripheral circulation may reﬂect an indi-
idual’s capacity to mount an effective immune response.
L ratio has been shown to correlate with inhibition of
ycobacterial growth in vitro10,11 and the risk is higher among
ndividuals with either low or high ML  ratio.12 These results
dd to evidence supporting that extremes of immunity are
ssociated with TB. This ratio could herald a previously
nknown pathophysiologic change of TB. As demonstrated by
ur study, patients with active tuberculosis had a higher or
ower ML  ratio compared to healthy donors. We stratiﬁed par-
icipants into three categories with different ML ratios, andhealthy donors were mostly in the group of ML  ratio between
the 9th and 25th percentile, but patients were mainly in the
group of ML ratio greater than the 25th percentile and in the
group of ML ratio less than the 9th percentile (Table 2). ML
ratios in extreme percentiles were signiﬁcant predictors for
active tuberculosis.
The normal ML ratio is disrupted by Mtb  infection. It has
been reported recently that Mtb infection may alter subsets
of hematopoietic stem cells13 or directly infect bone marrow
mesenchymal stem cells.14 Studies in mice15 and humans16
have shown that subsets of hematopoietic stem cells have
distinct biases in the ratio of myeloid to lymphoid cells they
give rise to.17,18 The different proportion of myeloid biased or
lymphoid-biased hematopoietic stem cells may underlie the
peripheral difference of ML  ratio. Therefore, it is reasonable
that Mtb infection may alter hematopoietic stem cells such
that the ML ratio is altered. The change of monocytes and lym-
phocytes, reﬂected in their ratio, may affect patients’ ability to
respond to mycobacterial infection. Further work to explore
the pathophysiological involvement of the ML  ratio in TB may
yield new pathways to modify or prevent the disease.
ML ratio of patients aged more  than 60 years and extrapul-
monary tuberculosis are disrupted more  seriously than others.
The multivariate analysis indicated that, among patients diag-
nosed with active tuberculosis, to be aged more  than 60 years
and to have extrapulmonary tuberculosis were associated
with different ML  ratios of patients.
In order to further evaluate whether ML ratio could be
affected by anti-TB therapy, the difference between before
treatment and after therapy was analyzed (Fig. 3). The results
indicated that high ML ratio decreased, and low ML ratio
increased to be close to the ML ratio of healthy donors. It sug-
gested that ML ratio of patients may be changed with anti-TB
therapy and the alteration of ML ratio may also reﬂect the
effectiveness and phase of therapy.Our study has several limitations. The eligible patients
represented a fraction of the patients diagnosed with active
tuberculosis during the study period, raising a concern for a
selection bias. Nearly 60.8% (649/1068) of the patients were





























































































Fig. 3 – Ratio of monocytes to lymphocytes (ML  ratio) of patients, before treatment, after treatment and healthy donors. (A)
ML ratio of patients with ML  ratio greater than 25th percentile; (B) ML  ratio of patients with ML ratio less than the 9th
percentile; (C) ML  ratio of patients with ML  ratio between the 9th and 25th percentile. Data are presented with box plot
reporting the median values and the interquartile range (***p < 0.001). Median ML  ratio of patients changed to be close to
rhealthy donors with anti-tuberculosis treatment.
excluded. Whether the exclusion of these patients affected
the outcome is unknown. As a retrospective study, collecting
information from medical records ﬁlled in by other profession-
als is unavoidable but tends to be less accurate. Fortunately, at
the time of clinical assessment, although clinicians were not
blinded to the full blood count, they were not aware of this
hypothesis, thus diminishing diagnostic bias.
Despite these limitations, our results support that ML ratios
are disrupted with tuberculosis; ML  ratios in the extreme per-
centiles are associated with active TB. This observation needs
to be conﬁrmed in other geographic settings.Conﬂicts  of  interest
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